MAPT and Alzheimer disease: [18F]flortaucipir (Figure 5a) PET in conjunction with post mortem pathology reliably detected Braak VI tau pathology, but the tracer was not sensitive to Braak I–IV tau pathology in AD patients compared with young tau-negative HCs [156].